Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,203.20
(
0.00%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
100.92
(
-0.28%
)
Bitcoin
78,141.70
(
-0.17%
)
News Focus
News Focus
Post# of 257441
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122884
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ronpopeil post# 238154

Wednesday, 05/26/2021 4:36:01 PM

Wednesday, May 26, 2021 4:36:01 PM

Post# of 257441
MYOV/PFE—What the FDA approved today was not Relugolix per se, but rather a fixed-dose-combination of Relugolix with estradiol and norethindrone.

Relugolix by itself was previously FDA-approved for prostate cancer under the brand name, Orgovyx (#msg-160319692).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today